Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

SOLIDARITY (interferon)
  NCT04315948		 RCTIFN beta-1acontrolCOVID 19 hospitalizedsome concern
2063/2064 inconclusive 14% 4%

COVID-19 mild to moderate meta-analysis

Fu
  ChiCTR2000030262		 RCTinterferon / TFF2standard of careCOVID-19 mild to moderatesome concern
40/40 conclusif 0%
Jagannathan
  NCT04331899		 RCTpeginterferonplaceboCOVID-19 mild to moderatesome concern
60/60 inconclusive

COVID-19 severe or critically meta-analysis

Darazam (COVIFERON Interferon beta-1a)
  NCT04343768		 RCTinterferonstandard of careCOVID-19 severe or criticallysome concern
20/20 suggested -63% 122%
Darazam (COVIFERON Interferon beta-1b)
  NCT04343768		 RCTIFN beta-1bstandard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive -43%
Kalil (ACTT-3)
  NCT04492475		 RCTIFN beta-1aplaceboCOVID-19 severe or criticallysome concern
487/482 inconclusive 67% -1%
Rahmani
  IRCT20100228003449N2		 RCTIFN beta-1bstandard of careCOVID-19 severe or criticallysome concern
40/40 conclusif -64%
4 studies excluded by filtering options (2 RCT / 2 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons